Evidence of the long-term benefits of the reversal of fibrosis on clinical outcome, such as a reduction in portal hypertension or the rate of development of hepatocellular carcinoma, is needed.[87] Although there are no definite and effective antifibrogenic agents, possible candidates are antioxidants,[88, 89] interferons,[90] flavonoids,[91] renin-angiotensin system inhibitors,[92–94] endothelin receptor antagonists,[95] and peroxisome proliferator activated receptor-gamma (PPAR-gamma) agonists.[96, 97]. The gene discussed is PPARG; the disease is liver disorder.